CYTOTECHNOLOGY, an esteemed journal published by Springer, stands as a vital resource in the fields of Bioengineering, Biomedical Engineering, and Biotechnology. With an impact factor reflective of its solid position within academia, this journal encompasses a broad scope dedicated to the advancement of cytotechnological research and applications from its inception in 1987 through to its latest volumes in 2024. Based in the Netherlands, it is committed to providing researchers, professionals, and students with high-quality, peer-reviewed articles that contribute to the understanding and innovations in cytotechnology. Although currently not open access, CYTOTECHNOLOGY has garnered a commendable reputation, holding Q3 rankings in multiple categories, indicating its relevance and influence within the scientific community. Researchers are encouraged to submit their cutting-edge findings to share insights that can spark further advancements in this dynamic field.

Biomolecules & Therapeutics is a prominent journal published by the Korean Society of Applied Pharmacology, dedicated to advancing knowledge in the fields of Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With an ISSN of 1976-9148 and an E-ISSN of 2005-4483, this journal serves as a vital platform for researchers and professionals to disseminate their findings from 2008 through 2024. Ranking in the Q2 category across multiple relevant fields, including Pharmacology and Drug Discovery, and consistently placing in the 60th to 70th percentiles in Scopus rankings, Biomolecules & Therapeutics exemplifies a commitment to high-quality research and scientific integrity. Although it operates on a traditional access model, readers can be assured of the journal's rigorous peer-review process, ensuring that published articles contribute meaningfully to ongoing discourse in pharmacological and biochemical research. Located in Seoul, South Korea, the journal stands at the forefront of innovation in healthcare, making it an essential resource for academics, students, and industry professionals alike.

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

Asian Journal of Pharmaceutical Sciences is a prestigious open-access journal published by Shenyang Pharmaceutical University, dedicated to advancing research and developments in the field of pharmaceutical sciences. Since its inception in 2009, the journal has successfully converged a wealth of knowledge and innovation, demonstrating an impressive track record with its open access model adopted in 2013, ensuring global dissemination of crucial research findings. With an outstanding impact factor and consistently ranked in the Q1 category for both Pharmaceutical Science and Pharmacology in 2023, it ranks among the top journals in its field, as evidenced by its impressive Scopus rankings—4th out of 183 in Pharmaceutical Science and 10th out of 313 in Pharmacology, showcasing its high relevance and credibility (98th and 96th percentiles respectively). Researchers, professionals, and students can access a diverse array of articles that encompass groundbreaking studies, reviews, and reports, solidifying the journal's position as a vital resource for anyone engaged in pharmaceutical research. With its commitment to quality and accessibility, Asian Journal of Pharmaceutical Sciences plays an essential role in fostering innovation and collaboration within the global scientific community.

The Biomedical Journal, published by ELSEVIER, serves as a premier platform for disseminating groundbreaking research in the field of medicine, specifically within the Q1 category of Medicine (Miscellaneous). With the ISSN 2319-4170 and E-ISSN 2320-2890, this Open Access journal has been committed to advancing biomedical science since its inception in 2002. With an impressive Scopus rank of #31 out of 636 in General Medicine and a notable placement in the 95th percentile, the journal provides valuable insights and rigorous studies that contribute significantly to the medical community. Based in the Netherlands at RADARWEG 29, 1043 NX AMSTERDAM, the journal is highly regarded for its timely and diverse range of articles, fostering collaboration and innovation amidst researchers, professionals, and students alike. The ongoing engagement in the journal's converged years from 2012 to 2024 underscores its commitment to keeping pace with the evolving landscape of biomedical research, making it an essential resource for those seeking to stay at the forefront of medical advancements.

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

Journal of Extracellular Vesicles, published by WILEY, stands at the forefront of research in the evolving fields of Cell Biology and Histology as a prestigious open-access journal that has been disseminating groundbreaking findings since 2012. With a commendable impact exemplified by its Q1 ranking in both categories for 2023, this journal offers an invaluable platform for researchers, professionals, and students to explore the critical roles of extracellular vesicles in cellular communication, disease pathology, and therapeutics. The journal is indexed in leading databases, ensuring wide visibility and accessibility of its content, which supports the collaborative spirit of scientific discovery. Featuring innovative research and comprehensive reviews, the Journal of Extracellular Vesicles not only maintains a high standard of scholarship but also fosters a community dedicated to advancing our understanding of these small yet significant cellular components.

JOURNAL OF DRUG TARGETING, published by Taylor & Francis Ltd, is a premier academic journal dedicated to advancing the field of pharmaceutical sciences with a strong focus on drug delivery and targeting methodologies. With an impressive impact factor and recognized as a Q1 journal in the Pharmaceutical Science category, it ranks #23 out of 183 in Pharmacology, Toxicology and Pharmaceutics, placing it within the top 13% of journals in its field. The journal provides a platform for interdisciplinary research, showcasing innovative techniques and breakthrough findings that serve to improve therapeutic efficacy through precision targeting. Although it operates under a subscription model, researchers benefit from extensive access to pivotal studies spanning from 1986 to 2024. The JOURNAL OF DRUG TARGETING aims to foster collaboration among academics, professionals, and students, making it an essential resource for those seeking to leverage the latest advancements in drug development and delivery systems for improved healthcare outcomes.

Nanomedicine-Nanotechnology Biology and Medicine is a leading journal published by Elsevier, dedicated to the exploration of innovative applications of nanotechnology in the fields of biology and medicine. With an ISSN of 1549-9634 and an E-ISSN of 1549-9642, this esteemed journal provides a platform for high-quality research, comprehensively covering areas including bioengineering, biomedical engineering, pharmaceutical science, and nanoscience. Notably, it holds a significant position in various categories with a Q2 ranking in multiple disciplines and a prestigious Q1 ranking in Pharmaceutical Science, emphasizing its impact within the scientific community. By facilitating access to cutting-edge studies and advancements, Nanomedicine-Nanotechnology Biology and Medicine serves as an essential resource for researchers, professionals, and students alike, contributing significantly to the ongoing development of nanomedicine and its pivotal role in improving healthcare outcomes. The journal operates without open access; however, it remains committed to disseminating valuable knowledge to a global audience.

CYTOKINE & GROWTH FACTOR REVIEWS, published by Elsevier Science Ltd, serves as a premier platform for the dissemination of cutting-edge research in the fields of Biochemistry, Genetics and Molecular Biology, Endocrinology, and Immunology. With an impressive impact factor that places it in the Q1 category across multiple disciplines, the journal brings together high-quality reviews that critically evaluate recent advances in cytokine and growth factor biology. This ensures that researchers and professionals have access to valuable insights that enhance current knowledge and stimulate further investigation. Although it is not an open-access journal, its rigorous selection process and high ranking – including Rank #7 in Medicine: Endocrinology, Diabetes and Metabolism – underscore its significance within the scientific community. With its converged years of publication from 1996 to 2024, CYTOKINE & GROWTH FACTOR REVIEWS remains a crucial resource for students, researchers, and professionals alike, informing their work with comprehensive overviews of key topics in the dynamic interplay of growth factors and cytokines.